Contineum Therapeutics opened lower at $10.71, compared with its previous close of $10.77. In the last trading session, the stock traded between $9.74 and $10.89. It showed a downward intraday trend.
An investment of $100 made 3 years ago in Contineum Therapeutics is now worth
$ 63.47
Resulting in a loss of
$ 36.53 (36.53%)
Note: Past profits do not guarantee future returns.
Rating from 7 Analysts
Today's Change
$-1.00 (-9.25%)
Day High
$10.89
Day Low
$9.74
Day Open
$10.71
Prev Close
$10.77
Volume
2,50,804
1W Return
0.06%
1M Return
13.98%
3M Return
-34.20%
6M Return
-28.40%
1Y Return
-10.82%
Market Cap ($ Mn)
346
PE Ratio
-
PB Ratio
2.68
PEG Ratio
-
ROE
-30.12%
ROCE
-33.47%
EPS (TTM)
-
1 Week
0.06%
1 Month
13.98%
3 Months
-34.20%
6 Months
-28.40%
9 Months
-35.95%
Contineum Therapeutics selects Qureight biomarker for Phase 2 IPF trial
Contineum Therapeutics selected Qureight’s Fibr8™ as a secondary endpoint for its Phase 2 PROPEL-IPF trial. The trial evaluates PIPE-791, targeting LPAR1, in approximately 324 idiopathic pulmonary fibrosis patients. Fibr8™ measures fibrosis extent on HRCT, complementing the primary endpoint of Forced Vital Capacity (FVC). The decision follows Qureight’s recent advocacy in the European Respiratory Journal for quantitative imaging in antifibrotic trials.
3 days agoJones Trading raises Contineum Therapeutics price target to $30
Jones Trading raised the price target for Contineum Therapeutics to $30. The previous price target was set at $24. The firm maintained a Buy rating on the stock. Analyst Debanjana Chatterjee issued the revised recommendation.
28 days agoContineum Therapeutics shares fall 29% on rival BMS trial data
Contineum Therapeutics shares declined 29.30% to $9.46 on Monday. Bristol Myers Squibb's admilparant failed to reach statistical significance at the 120 mg dose in Phase 3 trials. The 60 mg dose of admilparant significantly slowed lung function decline over 52 weeks. Contineum's lead asset PIPE-791 is in Phase 2 PROPEL-IPF study involving 324 patients.
1mo agoContineum's MOONLIGHT-1 trial misses primary efficacy endpoint
Contineum's Phase 2 MOONLIGHT-1 trial missed its primary efficacy endpoint for JNJ-5120/PIPE-307. The primary measure was improvement in MADRS total score at Day 5 versus placebo. No new safety signals were observed, indicating the drug was well-tolerated. Johnson & Johnson continues to analyze data including prespecified exploratory endpoints.
1mo agoContineum Therapeutics to present at 2026 Morgan Stanley Healthcare Conference
Contineum Therapeutics management to present at 2026 Morgan Stanley Global Healthcare Conference. Fireside chat scheduled for September 15 at 5:35 p.m. ET. Audio webcast and replay available via company website Investors section. Pipeline includes PIPE-791 for pulmonary fibrosis and PIPE-307 for depression.
2mo agoContineum Therapeutics beats Q2 EPS, extends cash runway to mid-2029
Contineum Therapeutics delivered better-than-expected Q2 2026 results with an EPS loss of $(0.40), driven by a 10% drop in R&D expenses to $12.7 million. The company affirmed a cash runway through mid-2029, supporting its global IPF trial and recent positive data in chronic pain.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 3 years ago in Contineum Therapeutics is now worth
$ 63.47
Resulting in a loss of
$ 36.53 (36.53%)
Note: Past profits do not guarantee future returns.
